15 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Fragment-Based Discovery of 2-Aminoquinazolin-4(3H)-ones As Novel Class Nonpeptidomimetic Inhibitors of the Plasmepsins I, II, and IV.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Latvian Institute of Organic Synthesis
Plasmepsin inhibitory activity and structure-guided optimization of a potent hydroxyethylamine-based antimalarial hit.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Latvian Institute of Organic Synthesis
alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Uppsala University
Expedient solid-phase synthesis of both symmetric and asymmetric diol libraries targeting aspartic proteases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
National University of Singapore
High antiplasmodial activity of novel plasmepsins I and II inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Milan
Synthesis of malarial plasmepsin inhibitors and prediction of binding modes by molecular dynamics simulations.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Uppsala University
Design and synthesis of potent inhibitors of plasmepsin I and II: X-ray crystal structure of inhibitor in complex with plasmepsin II.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
LinköPing University
Plasmepsin Inhibitors in Antimalarial Drug Discovery: Medicinal Chemistry and Target Validation (2000 to Present).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Zambia
Peptidomimetic plasmepsin inhibitors with potent anti-malarial activity and selectivity against cathepsin D.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Latvian Institute of Organic Synthesis
2-Aminoquinazolin-4(3H)-one based plasmepsin inhibitors with improved hydrophilicity and selectivity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Latvian Institute of Organic Synthesis
Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Novartis Pharmaceuticals
Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Abbott Laboratories
Stereospecific high-affinity TRPV1 antagonists: chiral N-(2-Benzyl-3-pivaloyloxypropyl) 2-[4-(methylsulfonylamino)phenyl]propionamide analogues.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Seoul National University